Release Date: October 19, 2023
Expiration Date: October 19, 2024
Time to Complete: 15 minutes
Format: Internet‐based Video
Maximum Credits:
0.25 / AMA PRA Category 1 Credit TM
0.25 / CNE Contact Hour
Target Audience
This educational initiative will primarily target medical oncologists (and residents/fellows specializing in oncology) working in community settings within the United States who treat patients with NSCLC. Given the reliance upon the oncology team to ensure patient engagement, while also effectively monitoring and managing adverse events, the oncology care team will definitely benefit from this type of initiative (to include oncology nurses, nurse navigators, oncology nurse practitioners and physician assistants).
Statement of Purpose
The overall concept for this educational initiative for community oncologists is to address unmet educational needs and positively impact practice change behaviors by accelerating the dissemination of new information. This initiative will be delivered in a pragmatic format designed to provide relevant and actionable information to the target audience where they are already engaging - on social media platforms. Antidote will work with the faculty and thought leaders to identify and disseminate findings from new studies and recently-published data relevant to Non-small Cell Lung Cancer (NSCLC).
Learning Objectives
Upon completion of this educational activity, participants will be better able to:
- More confidently discuss the current state of the field related to include Next Generation Sequencing (NGS) testing for cancer and available NSCLC treatment options.
- Consider the evidence related to how to most effectively treat and manage patients with NSCLC.
Educational Grant
This CME activity is supported by an unrestricted educational grant from Daiichi Sankyo.
Presenting Faculty
Charu Aggarwal, MD, MPH – Dr. Aggarwal is the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine. Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of personalized therapeutic approaches, and the discovery and application of biomarkers to guide treatment. She is a world-renowned expert in the application of plasma-based gene sequencing in the management of patients with metastatic lung cancer, and is actively working on implementation of comprehensive testing, and discovery of approaches focusing on early detection, detection of resistance mutations and disease monitoring.
Dr. Aggarwal serves as the Associate Director of Penn Center for Precision Medicine, and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I). In her roles, she is actively involved in developing, implementing, and advancing strategic and operational precision medicine initiatives with a focus on those that involve bringing new technologies or approaches to clinical care and ultimately deliver on the promise of personalized cancer therapy.
She is an active member of the Abramson Cancer Center where she serves as Physician Leader for the clinical research program for Airways Malignancies. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung Cancer.
Narjust Florez, MD – Dr. Narjust Florez, a Venezuelan-born physician, excelled in her medical education. She's a distinguished thoracic medical oncologist, the Associate Director of The Cancer Care Equity Program at Dana-Farber Cancer Institute, and an Assistant Professor of Medicine at Harvard Medical School. In 2022, she made history as the first Latina Associate Editor for Diversity, Equity, and Inclusion at JAMA Oncology. Her clinical expertise lies in targeted therapy for lung cancer and the unique care of women and young lung cancer patients. Dr. Florez is a renowned researcher in cancer health disparities, addressing gender and racial discrimination in medical practice. She founded the Florez Lab in 2019, focusing on lung cancer, social justice in medicine, and medical education. Her impactful work spans over 115 scientific publications and numerous awards, making her an influential figure in the field.
Howard (Jack) West, MD – Dr. West is a thoracic oncology specialist and an Associate Professor in Medical Oncology at City of Hope Comprehensive Cancer Center. He also serves as Vice President and Senior Medical Director of Access Hope, which is a program offering remote cancer consult services.
Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA.
After serving for over 16 years as Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, he moved to the City of Hope in 2019 to dedicate his focus on innovative approaches to delivering sub-specialist expertise beyond one region, using tools such as remote case reviews and telemedicine consultations.
He has authored dozens of papers and chairs several CME programs and symposia internationally on thoracic oncology, novel educational approaches, and social media in cancer care.
In addition to these activities, he is the Founder & President of Global Resource for Advancing Cancer Education (GRACE); Web Editor for JAMA Oncology; regular correspondent for Medscape; and contributing author and section editor in Lung Cancer for UpToDate.
Content Planning Faculty
Rahul Gosain, MD – Dr. Rahul Gosain is the Medical Director of Wilmot Cancer Institute at Webster and the Director of Wilmot Cancer Institute Regional Infusion services. Importantly, he is also a clinician who sees a wide variety of solid and hematologic malignancies in community settings. Alongside Dr. Rohit Gosain, through the "Oncology Brothers" platform, he spearheads campaigns to raise the bar and close the gap in cancer care between academia and community settings.
Rohit Gosain, MD – Dr. Rohit Gosain is the Chair of Medical Hematology/Oncology Department and VP of the Medicine Department at the UPMC Chautauqua Hospital - UPMC Hillman Cancer Center. He serves the community of Chautauqua, NY addressing wide range of malignancies, including solid and hematological. Additionally, he offers his community-leading expertise in oncology as one of the "Oncology Brothers" - with the aim to reiterate the standard of care options in this ever-changing field of oncology.
Accreditation
This activity is provided by Antidote Education Company.
Physicians: Antidote Education Company is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Antidote designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. Nurses may receive a maximum of 0.25 contact hour for completing the activity.
Method of Participation
- Register/Sign In.
- Read the learning objectives and disclosures.
- View the entire video.
- Complete post‐test with a score of 70% or better.
- Complete the evaluation and submit.
- A certificate will be emailed to you within 2 weeks.
For more information about the accreditation of this program, please contact Antidote Education Company at [email protected].
Disclosure
In accordance with The Standards for Integrity and Independence in Accredited Continuing Education promulgated by the Accreditation Council for Continuing Medical Education (“ACCME”), it is the policy of Antidote Education Company that all individuals in a position to control the content of an activity disclose all financial relationships with any ineligible company to Antidote prior to the activity. A relevant financial relationship is defined as any financial relationship in any amount occurring within the past 24 months with an ineligible company. A relevant financial relationship exists when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he or she has a financial relationship. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Antidote has established mechanisms to mitigate any relevant financial relationships disclosed or otherwise identified to ensure independence in all of its educational activities. If, through the application of these mechanisms, an individual’s relevant financial relationships cannot be resolved, that individual is prohibited from participating in the activity in question in any manner.
The relevant financial relationships, if any, of the individuals in a position to control the content of this educational activity have been mitigated through Antidote’s conflict resolution mechanism. Nonetheless, the relevant financial relationships, if any, of each individual in a position to control the content of this educational activity have been disclosed to you in the following section of this handout entitled “Disclosures.” If an individual has no relevant financial relationships, that fact is also provided to you.
Faculty Disclosures
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
University of Pennsylvania
Philadelphia, PA
Dr. Aggarwal, speaker for this educational activity, is a Consultant for AstraZeneca, Blueprint Genetics, Celgene Corporation, Daiichi Sankyo/AstraZeneca, Eisai Co., Ltd., Genentech, Inc., Lilly, Merck & Co., Regeneron/Sanofi, and Shionogi Inc., and has been provided Research Funding (if PI or named investigator) from AstraZeneca/MedImmune LLC, Genentech/Roche, Incyte, MacroGenics, Inc., and Merck Sharp & Dohme.
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Dr. Florez, speaker for this educational activity, is an Advisor for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Pfizer Inc., and Regeneron Pharmaceuticals, Inc.; received Research funding (if PI or named investigator) from Genentech, Inc.; and a Researcher for Mirati Therapeutics, Inc.
Howard (Jack) West, MD
Associate Professor, Medical Oncology
City of Hope Comprehensive Cancer Center
Vice President of Network Strategy, AccessHope
Los Angeles, CA
Dr. West, speaker for this educational activity, is a Consultant for AbbVie Inc., Amgen Inc., AstraZeneca, Daiichi Sankyo, Genentech/Roche Group, Gilead Sciences, Inc., Merck & Co., Mirati Therapeutics, Inc., Regeneron, Summit Therapeutics, Takeda Pharmaceutical Company, and a Speaker for AstraZeneca and Merck & Co.
Rahul Gosain, MD
Oncology Brothers
Medical Director, Wilmot Cancer Center in Webster
Wilmot Cancer Institute - University of Rochester School of Medicine
Rochester, NY
Dr. Gosain, planner and speaker for this educational activity, is a Consultant for AstraZeneca and Gilead Sciences, Inc.
Rohit Gosain, MD
Oncology Brothers
Chair of Medical Hematology/Oncology
UPMC Chautauqua Hospital
Jamestown, NY
All of the relevant financial relationships listed for these individuals above have been mitigated.
Planners’ and Manager’s Disclosures
The following planners, content reviewer, and writer/editor have reported that they do not have any relevant financial relationships with ACCME-defined ineligible companies during the past 24 months: Rohit Gosain, MD; Matthew Fleming; Michael Fleming, MD; Laura Irvin, MHL, RN, BSN; and Emma Hitt Nichols, PhD.
Disclosure of Unlabeled Use
Antidote Education Company requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will not discuss any “off-label” substance(s)/product(s) not approved by the FDA.
Disclaimer
The material presented at this course is being made available by Antidote Education Company for educational purposes only. This material is not intended to represent the only, nor necessarily best methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations. Opinions expressed in this activity are those of the faculty and not of Antidote. Every effort has been made to assure the accuracy of the data presented at this course. Physicians may care to check specific details prior to clinical application.